Ibrutinib: Uses, Mechanism of Action & Side Effects
Ibrutinib is a targeted cancer medication used to treat certain blood cancers. It works by blocking a specific enzyme that cancer cells need to grow and survive.
Things worth knowing about "Ibrutinib"
Ibrutinib is a targeted cancer medication used to treat certain blood cancers. It works by blocking a specific enzyme that cancer cells need to grow and survive.
What is Ibrutinib?
Ibrutinib is a kinase inhibitor belonging to the class of targeted cancer therapies. More specifically, it is a BTK inhibitor (Bruton's tyrosine kinase inhibitor), available as an oral capsule or tablet. It has been approved by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) and represents a major advance in the treatment of blood cancers.
Indications – When is Ibrutinib Used?
Ibrutinib is approved for the treatment of several hematologic malignancies (blood cancers), including:
- Chronic Lymphocytic Leukemia (CLL): the most common type of leukemia in adults
- Mantle Cell Lymphoma (MCL): an aggressive form of non-Hodgkin lymphoma
- Waldenstrom Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL): a rare lymphoma type
- Marginal Zone Lymphoma (MZL): in patients who have received prior therapy
- Chronic Graft-versus-Host Disease (cGvHD): following stem cell transplantation
Ibrutinib may be used as a single agent (monotherapy) or in combination with other cancer treatments.
Mechanism of Action
Ibrutinib works by selectively and irreversibly inhibiting the enzyme Bruton's Tyrosine Kinase (BTK). BTK is a critical component of the B-cell receptor (BCR) signaling pathway, which regulates the growth, proliferation, and survival of B-lymphocytes (a type of white blood cell).
In many blood cancers, malignant B-cells depend on this pathway to survive. By covalently binding to BTK, ibrutinib blocks downstream signaling, resulting in:
- Inhibition of cancer cell proliferation
- Reduced migration of cancer cells into lymphoid tissues and bone marrow
- Induction of programmed cell death (apoptosis) in cancer cells
This targeted approach makes ibrutinib more selective than conventional chemotherapy agents.
Dosage and Administration
Ibrutinib is taken once daily by mouth, swallowed whole with water. The recommended dose varies by indication:
- CLL/SLL: 420 mg per day
- MCL: 560 mg per day
- Waldenstrom Macroglobulinemia: 420 mg per day
- Chronic GvHD: 420 mg per day
Treatment is generally continued long-term as long as the disease is controlled and the medication is tolerated. Dosage should always follow medical prescription and current clinical guidelines.
Side Effects
Like all cancer medications, ibrutinib may cause side effects. Commonly reported side effects include:
- Bleeding: increased risk of bruising and bleeding, even from minor injuries
- Infections: increased susceptibility to bacterial, viral, and fungal infections due to immune suppression
- Cardiac arrhythmias: particularly atrial fibrillation, a clinically important concern
- High blood pressure (hypertension)
- Diarrhea, nausea, and vomiting
- Muscle and joint pain
- Skin rash
- Fatigue and weakness
- Changes in blood counts (e.g., neutropenia, thrombocytopenia)
Patients should promptly inform their physician if they experience unusual bleeding, irregular heartbeat, or signs of infection.
Drug Interactions and Contraindications
Ibrutinib is primarily metabolized by the liver enzyme CYP3A4. Certain medications and foods can therefore significantly affect ibrutinib levels in the blood:
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) increase ibrutinib plasma levels and the risk of side effects
- Strong CYP3A4 inducers (e.g., rifampin, phenytoin, St. John's Wort) decrease ibrutinib levels and may reduce effectiveness
- Concurrent use of anticoagulants (e.g., warfarin) should be approached with caution due to increased bleeding risk
Before starting ibrutinib, patients should discuss all medications, supplements, and herbal products they are taking with their treating physician.
References
- European Medicines Agency (EMA): Imbruvica (Ibrutinib) – Summary of Product Characteristics. EMA, 2024. Available at: www.ema.europa.eu
- Burger J.A. et al. – Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine, 373(25):2425–2437, 2015.
- Wang M.L. et al. – Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 369(6):507–516, 2013.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categorySagittal Split Osteotomy
Sacroiliac joint syndrome
Salter-Harris fracture
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Ibrutinib